Standardized myrtol attenuates lipopolysaccharide induced acute lung injury in mice

References

• Abraham E, Carmody A, Shenkar R, Arcaroli J. 2000. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 279:L1137–L1145.
   PubMed Web of Science ®Google Scholar
• Bauer TT, Montón C, Torres A, Cabello H, Fillela X, Maldonado A, Nicolás JM, Zavala E. 2000. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 55:46–52.
   PubMed Web of Science ®Google Scholar
• Begrow F, Böckenholt C, Ehmen M, Wittig T, Verspohl EJ. 2012. Effect of Myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parameters. Adv Ther. 29:350–358.
   PubMed Web of Science ®Google Scholar
• Beuscher N, Kietzmann M, Bien E, Champeroux P. 1998. Interference of Myrtol standardized with inflammatory and allergic mediators. Arzneimittelforschung. 48:985–989.
   PubMed Web of Science ®Google Scholar
• Bhatia M, Moochhala S. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 202:145–156.
   PubMed Web of Science ®Google Scholar
• Cao L, Chen Y, Zhao Y, Zhang H, Wang S, Wang Z, Kang J. 2011. Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease. Arzneimittelforschung. 61:685–692.
   PubMed Web of Science ®Google Scholar
• Chen H, Bai C, Wang X. 2010. The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev Respir Med. 4:773–783.
   PubMedGoogle Scholar
• Galvin IM, Steel A, Pinto R, Ferguson ND, Davies MW. 2013. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 7:CD003707.
   Google Scholar
• Grassmann J, Hippeli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF. 2000. Antioxidant properties of essential oils. Possible explanations for their anti-inflammatory effects. ArzneimittelForschung. 50:135–139.
   PubMed Web of Science ®Google Scholar
• Grommes J, Soehnlein O. 2011. Contribution of neutrophils to acute lung injury. Mol Med. 17:293–307.
   PubMed Web of Science ®Google Scholar
• Herridge MS, Angus DC. 2005. Acute lung injury-affecting many lives. N Engl J Med. 353:1736–1738.
   PubMed Web of Science ®Google Scholar
• Lopez B, Maisonet TM, Londhe VA. 2015. Alveolar NF-κB signaling regulates endotoxin-induced lung inflammation. Exp Lung Res. 41:103–114.
   PubMed Web of Science ®Google Scholar
• Matthys H, de Mey C, Carls C, Ryś A, Geib A, Wittig T. 2000. Efficacy and tolerability of Myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. ArzneimittelForschung. 50:700–711.
   PubMed Web of Science ®Google Scholar
• Matute-Bello G, Frevert CW, Martin TR. 2008. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 295:L379–L399.
   PubMed Web of Science ®Google Scholar
• Meister R, Wittig T, Beuscher N, de Mey C. 1999. Efficacy and tolerability of Myrtol standardized in long-term treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group investigators. ArzneimittelForschung. 49:351–358.
   PubMed Web of Science ®Google Scholar
• Rantzsch U, Vacca G, Dück R, Gillissen A. 2009. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res. 14:205–209.
   PubMedGoogle Scholar
• Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. 2005. Incidence and outcomes of acute lung injury. N Engl J Med. 353:1685–1693.
   PubMed Web of Science ®Google Scholar
• Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, Colgan SP, Eltzschig HK. 2010. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol. 184:5271–5279.
   PubMed Web of Science ®Google Scholar
• Schuliga M. 2015. NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules. 5:1266–1283.
   PubMed Web of Science ®Google Scholar
• Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E. 1996. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med. 24:1285–1292.
   PubMed Web of Science ®Google Scholar
• Shi D, Zheng M, Wang Y, Liu C, Chen S. 2014. Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice. Pharm Biol. 6:729–734.
   Web of Science ®Google Scholar
• Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. 1994. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med. 150:113–122.
   PubMed Web of Science ®Google Scholar
• Takano Y, Mitsuhashi H, Ueno K. 2011. 1α,25-Dihydroxyvitamin D3 inhibits neutrophil recruitment in hamster model of acute lung injury. Steroids. 76:1305–1309.
   PubMed Web of Science ®Google Scholar
• Tunceroglu H, Shah A, Porhomayon J, Nader ND. 2013. Biomarkers of lung injury in critical care medicine: past, present, and future. Immunol Invest. 42:247–261.
   PubMed Web of Science ®Google Scholar
• Wang M, Liu T, Wang D, Zheng Y, Wang X, He J. 2011. Therapeutic effects of pyrrolidine dithiocarbamate on acute lung injury in rabbits. J Transl Med. 9:61.
   PubMed Web of Science ®Google Scholar
• Ying B, Maimaiti AK, Song D, Zhu S. 2015. Myrtol ameliorates cartilage lesions in an osteoarthritis rat model. Int J Clin Exp Pathol. 8:1435–1442.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Du Z, Zhou Q, Wang Y, Li J. 2014. Remifentanil attenuates lipopolysaccharide-induced acute lung injury by downregulating the NF-κB signaling pathway. Inflammation. 37:1654–1660.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Seiberling M, Thomann P, Karabelnik D. 1995. The relative bioavailability and pharmacokinetics of standardized Myrtol. ArzneimittelForschung. 45:1198–1201.
   PubMed Web of Science ®Google Scholar